649736-29-8

Basic information

• Product Name: methyl 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carboxylate
• Synonyms: methyl 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carboxylate;4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester;Ethyl 4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylat;Ethyl 4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxy;Ethyl 4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylate;methyl 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)
• CAS NO: 649736-29-8
• Molecular Formula: C19H17FN4O3
• Molecular Weight: 368.3616832
• EINECS: -0
• Mol File: 649736-29-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.41
• Storage Temp.: 2-8°C
• CAS DataBase Reference: methyl 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carboxylate(649736-29-8)
• EPA Substance Registry System: methyl 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carboxylate(649736-29-8)

Safety Data

• Hazardous Substances Data: 649736-29-8(Hazardous Substances Data)

Usage

General Description

Methyl 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carboxylate is a complex chemical compound with a molecular structure consisting of a methyl ester group attached to a pyrrolotriazine ring system. The compound contains a 4-fluoro-2-methyl-1H-indol-5-yloxy moiety, which is a substituted indole ring with a fluorine and methyl group attached. The chemical also features a fused pyrrolo[1,2-f][1,2,4]triazine core, which is a nitrogen-containing heterocyclic ring system. methyl 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carboxylate may have potential applications in various fields such as pharmaceuticals, agrochemicals, and materials science, and its specific properties and uses would require further characterization and study.

Upstream product

• 649736-31-2 1-(2-fluoro-3-hydroxy-6-nitrophenyl)propan-2-one 
• 288385-99-9 1-(2-fluoro-3-methoxy-6-nitrophenyl)propan-2-one 
• 121247-16-3 1-(2,3-difluoro-6-nitrophenyl)propan-2-one 
• 427878-70-4 ethyl 4-hydroxy-5-methylpyrrolo[2,1-f ][1,2,4]-triazine-6-carboxylate 
• 1022112-32-8 2-(2,3-difluoro-6-nitrophenyl)-3-oxobutanoic acid ethyl ester 
• 771-69-7 2,3,4-trifluoronitrobenzene 
• 427878-41-9 4-chloro-5-methyl-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester 
• 288385-88-6 4-fluoro-2-methyl-1H-indol-5-ol 

Downstream Products

• 649735-41-1 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol 
• 649736-30-1 2-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)propan-2-ol 

Relevant articles and documents

Commercial synthesis of a pyrrolotriazine-fluoroindole intermediate to brivanib alaninate: Process development directed toward impurity control

The development of a practical, commercial process for the preparation of 4-fluoro-2-methyl-indol-5-ol and its subsequent coupling with a pyrrolotriazine to form an advanced intermediate of the oncology therapy brivanib alaninate is described. A key aspect is the multikilogram-scale preparation of the fluoroindole intermediate from trifluoronitrobenzene and the subsequent coupling while achieving impurity minimalization. As brivanib alaninate is a high-dose drug, the synthesis of highquality API with low levels of impurities is critical.

PROCESS FOR PREPARING CERTAIN PYRROLOTRIAZINE COMPOUNDS

The present invention relates to a process for preparing certain pyrrolotriazine compounds of the formula (I) and pharmaceutically acceptable salts thereof. The formula (I) compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.